175 related articles for article (PubMed ID: 37902466)
1. Use of Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma: A Retrospective Case Collection.
Gosmann J; Stadler R; Quint KD; Gutzmer R; Vermeer MH
Acta Derm Venereol; 2023 Oct; 103():adv10306. PubMed ID: 37902466
[TBL] [Abstract][Full Text] [Related]
2. Comparison of pegylated interferon α-2b plus psoralen PUVA versus standard interferon α-2a plus PUVA in patients with cutaneous T-cell lymphoma.
Hüsken AC; Tsianakas A; Hensen P; Nashan D; Loquai C; Beissert S; Luger TA; Sunderkötter C; Schiller M
J Eur Acad Dermatol Venereol; 2012 Jan; 26(1):71-8. PubMed ID: 22168776
[TBL] [Abstract][Full Text] [Related]
3. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
4. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II.
Stadler R; Otte HG; Luger T; Henz BM; Kühl P; Zwingers T; Sterry W
Blood; 1998 Nov; 92(10):3578-81. PubMed ID: 9808550
[TBL] [Abstract][Full Text] [Related]
5. Photochemotherapy alone or combined with interferon alpha-2a in the treatment of cutaneous T-cell lymphoma.
Roenigk HH; Kuzel TM; Skoutelis AP; Springer E; Yu G; Caro W; Gilyon K; Variakojis D; Kaul K; Bunn PA
J Invest Dermatol; 1990 Dec; 95(6 Suppl):198S-205S. PubMed ID: 2258636
[TBL] [Abstract][Full Text] [Related]
6. Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA.
Mostow EN; Neckel SL; Oberhelman L; Anderson TF; Cooper KD
Arch Dermatol; 1993 Jun; 129(6):747-52. PubMed ID: 8507078
[TBL] [Abstract][Full Text] [Related]
7. Dose-escalation study evaluating pegylated interferon alpha-2a in patients with cutaneous T-cell lymphoma.
Schiller M; Tsianakas A; Sterry W; Dummer R; Hinke A; Nashan D; Stadler R
J Eur Acad Dermatol Venereol; 2017 Nov; 31(11):1841-1847. PubMed ID: 28557110
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of interferon-alpha-2a plus psolaren with ultraviolet light A in patients with cutaneous T-cell lymphoma.
Chiarion-Sileni V; Bononi A; Fornasa CV; Soraru M; Alaibac M; Ferrazzi E; Redelotti R; Peserico A; Monfardini S; Salvagno L
Cancer; 2002 Aug; 95(3):569-75. PubMed ID: 12209749
[TBL] [Abstract][Full Text] [Related]
9. Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Wollina U; Looks A; Meyer J; Knopf B; Koch HJ; Liebold K; Hipler UC
J Am Acad Dermatol; 2001 Feb; 44(2):253-60. PubMed ID: 11174383
[TBL] [Abstract][Full Text] [Related]
10. Interferon alpha and etretinate combination treatment of cutaneous T-cell lymphoma.
Zachariae H; Thestrup-Pedersen K
J Invest Dermatol; 1990 Dec; 95(6 Suppl):206S-208S. PubMed ID: 2258637
[TBL] [Abstract][Full Text] [Related]
11. Non-pegylated and Pegylated Interferon Alpha-2a in Cutaneous T-cell Lymphoma and the Risk of Severe Ocular Side-effects.
Albrecht JD; Ninosu N; Barry D; Albrecht T; Schaarschmidt ML; Goerdt S; Nicolay JP
Acta Derm Venereol; 2022 May; 102():adv00722. PubMed ID: 35506362
[No Abstract] [Full Text] [Related]
12. Systemic treatment for cutaneous lymphomas.
Mielke V; Staib G; Sterry W
Recent Results Cancer Res; 1995; 139():403-8. PubMed ID: 7597307
[TBL] [Abstract][Full Text] [Related]
13. Treatment of childhood cutaneous T-cell lymphoma with alpha-interferon plus PUVA.
Tay YK; Weston WL; Aeling JL
Pediatr Dermatol; 1996; 13(6):496-500. PubMed ID: 8987062
[TBL] [Abstract][Full Text] [Related]
14. Combination therapy of cutaneous T cell lymphoma with interferon alpha-2a and photochemotherapy.
Stadler R; Otte HG
Recent Results Cancer Res; 1995; 139():391-401. PubMed ID: 7597306
[TBL] [Abstract][Full Text] [Related]
15. Interferon and low doses of methotrexate versus interferon and retinoids in the treatment of refractory/relapsed cutaneous T-cell lymphoma.
Aviles A; Neri N; Fernandez-Diez J; Silva L; Nambo MJ
Hematology; 2015 Oct; 20(9):538-42. PubMed ID: 25592781
[TBL] [Abstract][Full Text] [Related]
16. Prognosis in early stage cutaneous T-cell lymphoma treated with psoralen plus ultraviolet A irradiation and low-dose interferon-α: Long-term efficacy and survival according to conventional and emerging clinical endpoints.
Rupoli S; Goteri G; Morsia E; Torre E; Giantomassi F; Campanati A; Offidani AM; Molinelli E; Brandozzi G; Serresi S; Giacchetti A; Bugatti L; Filosa G; Mozzicafreddo G; Simonacci M; Olivieri A
Dermatol Ther; 2022 Oct; 35(10):e15737. PubMed ID: 35903895
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic alternatives in cutaneous T-cell lymphoma.
Holloway KB; Flowers FP; Ramos-Caro FA
J Am Acad Dermatol; 1992 Sep; 27(3):367-78. PubMed ID: 1383293
[TBL] [Abstract][Full Text] [Related]
18. Management of refractory early-stage cutaneous T-cell lymphoma.
Huber MA; Staib G; Pehamberger H; Scharffetter-Kochanek K
Am J Clin Dermatol; 2006; 7(3):155-69. PubMed ID: 16734503
[TBL] [Abstract][Full Text] [Related]
19. The Use of Interferons in the Treatment of Cutaneous T-Cell Lymphoma.
Spaccarelli N; Rook AH
Dermatol Clin; 2015 Oct; 33(4):731-45. PubMed ID: 26433845
[TBL] [Abstract][Full Text] [Related]
20. Peginterferon alpha-2a (40 KD) plus ribavirin for the treatment of chronic hepatitis C in Japanese patients.
Kuboki M; Iino S; Okuno T; Omata M; Kiyosawa K; Kumada H; Hayashi N; Sakai T
J Gastroenterol Hepatol; 2007 May; 22(5):645-52. PubMed ID: 17444850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
